Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 407

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 407
---
 approval would be inappropriate, to another independent body of our Board, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant stockholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our code of conduct and ethics, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our Audit Committee, or other independent body of our Board, will take into account the relevant available facts and circumstances including, but not limited to:

| • |     | the risks, costs and benefits to us; |

| • |     | the impact on a director’s independence in the event that the related person is a director, immediate family 
 member of a director or an entity with which a director is affiliated;                                       |

| • |     | the availability of other sources for comparable services or products; and |

| • |     | the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. |

The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our Audit Committee, or other independent body of our Board, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our Audit Committee, or other independent body of our Board, determines in the good faith exercise of our discretion. 254

PRINCIPAL SECURITYHOLDERS The following table sets forth information regarding the beneficial ownership of our Common Stock as of March 31, 2025 by:

| • |     | each person or “group” known to be the beneficial owner of more than 5% of our outstanding Common 
 Stock;                                                                                            |

| • |     | each of our named executive officers and directors; and |

| • |     | all of our executive officers and directors as a group. |

Beneficial ownership